Trials / Recruiting
RecruitingNCT07126158
Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
Phase II Study of Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Advanced pancreatic cancer patients receiving treatment of adaptive stereotactic body radiotherapy (SBRT) with concurrent and adjuvant defactinib plus avutometinib will have increased progression-free survival (PFS) compared to historical PFS rates for patients receiving adaptive SBRT alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Stereotactic body radiotherapy | MRIdian and Ethos (adaptive radiation platforms) |
| DRUG | Defactinib | Taken with 30 minutes of a meal |
| DRUG | Avutometinib | Can be taken without regard to food. |
Timeline
- Start date
- 2026-04-10
- Primary completion
- 2030-04-30
- Completion
- 2030-04-30
- First posted
- 2025-08-17
- Last updated
- 2026-04-15
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT07126158. Inclusion in this directory is not an endorsement.